Stock Events

Stock Events

Clearmind Medicine 

$7.90
49
+$0.00+0% Friday 16:24

Statistics

Day High
-
Day Low
-
52W High
-
52W Low
-
Volume
-
Avg. Volume
-
Mkt Cap
0
P/E Ratio
-
Dividend Yield
-
Dividend
-

Earnings

31JulExpected
Q2 2016
Q3 2016
Q4 2016
Q3 2021
Q4 2021
Q1 2022
Q2 2022
-1.91
-1.28
-0.64
-0
Expected EPS
N/A
Actual EPS
-1.192

Financials

-Profit Margin
Unprofitable
2018
2019
2020
2021
2022
0Revenue
-7.27MNet Income

Competitors

This list is an analysis based on recent market events. It's not an investment recommendation.
Compass Pathways
CMPS
Mkt Cap1.84B
COMPASS Pathways is focused on psilocybin therapy for mental health conditions, competing in the psychedelic medicine sector alongside Clearmind Medicine.
AtaiBeckley
ATAI
Mkt Cap2.74B
ATAI Life Sciences is a biotech company developing treatments for mental health disorders, including psychedelic and non-psychedelic compounds, making it a competitor in the broader mental health treatment market.
GH Research
GHRS
Mkt Cap1.94B
GH Research is developing 5-MeO-DMT therapies for depression, a direct competitor in the psychedelic treatment market for mental health, similar to Clearmind's objectives.
Nuveen Municipal Income
NUMI
Mkt Cap0
Numinus Wellness is engaged in the development of psychedelic therapies and wellness services, competing in the same sector as Clearmind Medicine.
MiniMed Group
MMED
Mkt Cap6.55B
MindMedicine (MindMed) Inc. is another key player in the psychedelic medicine space, focusing on developing treatments for mental illness and addiction, directly competing with Clearmind Medicine.
Revive Therapeutics
RVVTF
Mkt Cap9.15M
Revive Therapeutics is exploring the use of psychedelics in treatments, including psilocybin for substance abuse, positioning it as a competitor in the psychedelic therapy market.

About

Clearmind Medicine Inc is a clinical-stage pharmaceutical company engaged in Phase I/IIa clinical trials of novel psychedelic medicines. The Company focuses on developing treatments for mental health disorders, including alcohol use disorder (AUD), binge drinking, and eating disorders. Its activities are centered on the research and development of 5-methoxy-2-aminoindane (MEAI). It operates through a single research and development segment, which is conducted in Israel.
Show more...
CEO
Adi Zuloff-Shani
Employees
2
Country
Canada
ISIN
CA1850532047
WKN
000A3DUN7

Listings

BOATS
BOATS
CMND.BOATS
MU
DE
CWY0.MU
STU
DE
CWY0.STU
MU
DE
CWY.MU

0 Comments

Share your thoughts

FAQ

What is Clearmind Medicine stock price today?▼
The current price of CMNDF is $7.90 USD — it has increased by +0% in the past 24 hours. Watch Clearmind Medicine stock price performance more closely on the chart.
What is Clearmind Medicine stock ticker?▼
Depending on the exchange, the stock ticker may vary. For instance, on OTCM exchange Clearmind Medicine stocks are traded under the ticker CMNDF.
What were Clearmind Medicine earnings last quarter?▼
CMNDF earnings for the last quarter are -0.03 USD per share, whereas the estimation was 0 USD resulting in a -∞% surprise. The estimated earnings for the next quarter are N/A USD per share.
What is Clearmind Medicine revenue for the last year?▼
Clearmind Medicine revenue for the last year amounts to 0 USD.
What is Clearmind Medicine net income for the last year?▼
CMNDF net income for the last year is -7.27M USD.
How many employees does Clearmind Medicine have?▼
As of September 09, 2026, the company has 2 employees.
In which sector is Clearmind Medicine located?▼
Clearmind Medicine operates in the Health & Wellness sector.
When did Clearmind Medicine complete a stock split?▼
The last stock split for Clearmind Medicine was on October 03, 2022 with a ratio of 1:30.
Where is Clearmind Medicine headquartered?▼
Clearmind Medicine is headquartered in Vancouver, Canada.